



5 **soho** Italy
SOCIETY OF HEMATOLOGIC ONCOLOGY
2023 ANNUAL
CONFERENCE
HYBRID EVENT

03 - 06 Oct 2023

A.Roma Lifestyle Hotel
Rome, Italy



PRESIDENTS

C. Cerchione, H. Kantarjian, G. Martinelli

SCIENTIFIC BOARD

K.C. Anderson, C. Cerchione, N. Daver, A. De La Fuente, C. DiNardo, A. Ferrajoli, G. Garcia-Manero, E. Jabbour, N. Jain, H. Kantarjian, H.C. Lee, T. Kadia, M. Konopleva, G. Martinelli, G. Musuraca, A. Paulus, F. Ravandi, G. Saglio

TOPICS

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma and MGUS, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, CAR-T and Cellular Therapy, Supportive care in hematological malignancies

Join Us
Become a Member



Follow us
#SOHOItaly



Organizing secretariat



www.proeventi.it
info@proeventi.it





Italian ECM Accreditation

The Conference has been accredited to the Italian Ministry of Health:

Event n. 390468

Provider n. 2773

ECM Credits n. 24.5 for:

Medical Surgeon (interdisciplinary area), Biologist, Pharmacist, TSLB, Nurse
Training objective 3: Clinical documentation. Diagnostic and rehabilitation
clinical-care pathways, care profiles - treatment profiles.

Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.



EBAH CME Accreditation

Continuing Medical Education (CME) is widely accepted to encourage individual practitioners to maintain and develop professional knowledge and skills keeping up-to-date with latest developments within the field. The meeting is accredited by the EBAH system. Participants of this meeting will receive 24.5 Credits following the entire Conference.




Patronage



In Association with



Promoted by



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**

**Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico**

ISTITUT
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI


provider n. 2773



info@proeventi.it
www.proeventi.it

SUMMARY

1	PARTNERSHIPS
3	SUMMARY
4	ABOUT SOHO ITALY
6	PRESIDENTS
7	SCIENTIFIC BOARD
11	SCIENTIFIC SECRETARIAT
12	FACULTY
18	KEY INFORMATION
19	GENERAL INFORMATION
20	PUBLIC TRANSPORT
22	PROGRAM TABLE
26	TUESDAY, OCT. 03 RD
31	WEDNESDAY, OCT. 04 TH
38	THURSDAY, OCT. 05 TH
43	FRIDAY, OCT. 06 TH
50	SUPPORTERS



What is SOHO Italy?

The Italian Society of Hematologic Oncology is bringing together leading SOHO experts and top Italian researchers in Acute Leukemias, Multiple Myeloma, Non-Hodgkin and Hodgkin Lymphomas, MPNs, MDS and rare diseases, and it aims to consolidate the Italian Hematology-SOHO partnership.

Purpose

The aim of the association is the integration of the clinical-scientific activities of Italy and MD Anderson Cancer Center and the improvement of the clinical-therapeutic approach to patients with hematologic malignancies.

Represented by

The society SOHO ITALY is represented by G. Martinelli and C. Cerchione (IRST IRCCS), H. Kantarjian, E. Jabbour N. Daver (MD Anderson Cancer Center) and M. Konopleva (Albert Einstein College of Medicine, New York)




PRESIDENTS

Claudio Cerchione



Since 2018, he works in Hematology Unit of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS. He also has spent international research experiences in Friedrich-wilhelms universität, Bonn, Germany, in Universidade de Coimbra, Portugal, collaborating in their clinical and research projects, and in MD Anderson Cancer Center, Houston, USA, where he was nominated Ambassador of SOHO (Society of Hematologic Oncology). He is member of the editorial boards of many scientific journals, and member of several international societies, including the Society of Hematologic Oncology (SOHO), American Society of Hematology (ASH), European Hematology Association (EHA).

Hagop Kantarjian



Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003 - present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian's research focuses on translational-clinical developmental therapeutics.

Giovanni Martinelli




As of 1 January 2018, Professor Giovanni Martinelli is scientific director of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS, in Meldola (FC), Italy. Until December 2017, Professor Giovanni Martinelli was associate professor of Hematology at the Institute of Hematology "L. & A. Seragnoli", Azienda Ospedaliera S. Orsola - Malpighi at the University of Bologna, Italy. His main fields of research are AML, ALL and CML, including research on targeted therapies in major hematological syndromes: Acute Leukemias, CML (both Philadelphia-chromosome positive and non - positive), and hypereosinophilic syndrome.



SCIENTIFIC BOARD

Claudio Cerchione, Hagop Katarjian, Giovanni Martinelli

Kenneth C. Anderson



Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

Naval G. Daver



Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He is a clinical investigator with a focus on molecular and immune therapies in AML and myeloid disease and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance.

Adolfo De La Fuente



Dr Adolfo de la Fuente has specialized in Onco-Hematology diseases, he is currently working at MD Anderson CC Madrid as Head of the Hematology Department and responsible for the Onco-hematology clinical trials Unit.

Dr. de la Fuente is a member of the Spanish Society of Hematology (SEHH) and the European Hematology Association (EHA).

He also has an active role in Spanish national working groups PETHEMA on Acute and Chronic Leukemia. He has been involved in numerous clinical trials focused on Leukemia and Lymphoma and has led studies on this area in Spain.



Courtney DiNardo



Dr. DiNardo interests are focused on inherited predispositions to hematologic malignancies. This interest led to the development of one of the first dedicated clinics for evaluation of families with hematologic malignancies in the country (Hereditary Hematologic Malignancy Clinic—HHMC) in April 2014. The HHMC provides research based opportunities for scientific discovery through whole exome sequencing families with a strong history of hematologic malignancies including the potential for novel gene discovery. My research in the evolving clinical phenotype and treatment outcomes of IDH1 and IDH2 mutations in myeloid malignancies has yielded numerous publications and national/international IDH-inhibitor trials.

Alessandra Ferrajoli



Dr. Ferrajoli is an academic hematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson since 1998. Her main area of interest includes the treatment and biology of chronic lymphocytic leukemia and its variants, and treatment of elderly patients with acute and chronic leukemia. In these fields Dr. Ferrajoli has authored and co-authored more than two hundred and fifty publications in peer reviewed journals. She serves on numerous journal editorial boards and grant proposal study sessions for several US and European Agencies.

Guillermo Garcia-Manero



Guillermo Garcia-Manero, M.D., is a physician-scientist specializing in state-of-the-art treatments for leukemia. His research focuses on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and his goal is develop and validate new therapeutics to treat these deadly diseases. He leads teams of clinicians, medical fellows, nurses, physician assistants and researchers to conduct pre-clinical, translational, and clinical studies. The goal of these studies is to understand, treat, and eventually cure MDS, AML and other leukemias.



Elias Jabbour



Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; 5) triple therapy in AML.

Nitin Jain



Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He then moved to the United States and completed his Internal Medicine residency training at the Medical College of Wisconsin, Milwaukee, Wisconsin. He then completed a year of clinical fellowship in Leukemia at MD Anderson Cancer Center followed by another year of Leukemia research fellowship at the Memorial Sloan-Kettering Cancer Center in New York. He then pursued fellowship in Hematology/Oncology at the University of Chicago.

Hans C. Lee



Hans C. Lee, MD, is an Assistant Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas where he focuses his efforts on the clinical care and research of patients with plasma cell dyscrasias. He has a particular interest and focus on early phase clinical trials and novel therapeutic approaches to relapsed and/or refractory multiple myeloma.



Tapan M. Kadia



Dr. Tapan Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL. He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these.

Marina Konopleva



Dr. Konopleva is a Physician-Scientist, Professor, and active member of the clinical faculty in the Departments of Leukemia and Stem Cell Transplantation. Her laboratory is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. Dr. Konopleva has extended her research to include clinical translational investigations and has developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs.

Gerardo Musuraca



Dr. Musuraca is the Chief of Hematology Unit at IRST – IRCCS, in Meldola (FC), Italy. After a degree cum laude at the University of Bologna and a specialization in Hematology, since January 2006 he has been a PhD student in Clinical and Experimental Hematology at the University of Bologna. In 2007 he began the Clinical activity and research at Cancer Institute of Romagna. He is also Abstracts Reviewer and moderator on lymphoma, preclinical and biological agents of the American Society of Hematology meeting (ASH) and in December 2011 he reached a highly specialized position on Lymphomas at the Cancer Institute of Romagna.



Aneel Paulus



As a translational scientist, Aneel Paulus, M.D., conducts scientific investigations that seek to address the clinical challenges of patients with hematologic cancers. Because there is an incomplete molecular understanding of these challenges, Dr. Paulus centers his research on the biomolecular and immunologic mechanisms associated with drug resistance in B-cell cancers.

Dr. Paulus' team utilizes advanced computational, genomic and immunology-based techniques to study the effects of targeted-therapies on tumor-cell signaling pathways and how this influences their interaction with the innate and adaptive immune system.

Farhad Ravandi-Kashani



Dr. Farhad Ravandi is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center. Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.

Giuseppe Saglio



Giuseppe Saglio is Full Professor of Internal Medicine and Hematology at the University of Turin. He graduated from the University of Turin in 1975. Since then he has studied Internal Medicine at the University of Turin (1975-1980), Hematology at the University of Milan (1980-1983), and Molecular Biology at the University of Leiden (1976), Inserm-Creteil, Paris (1979) and at the University of California (1983). Prof. Saglio is coordinator of the PhD program in Molecular Medicine at the University of Turin, past-president of the Italian Society of Experimental Hematology (SIES) and is a member of the Academy of Medicine of Turin.

SCIENTIFIC SECRETARIAT

Claudio Cerchione, Giovanni Martinelli, Gerardo Musuraca



FACULTY

Elisabetta **Abruzzese**

Sikander **Ailawadhi**

Kenneth C. **Anderson**

Micheal **Andreeff**

Niccolo' **Bolli**

Giuliano **Bolondi**

Cirino **Botta**

Benedetto **Bruno**

Gabriele **Buda**

Natalie S. **Callander**

Amanda **Cashen**

Claudio **Cerchione**

Asher **Chanan-Khan**

Daniela **Cilloni**

Simona **Colla**

Elena **Crisà**

Antonio **Cuneo**

Naval **Daver**

Matteo **Da Vià**

Adolfo **De La Fuente**

Carmino **De Souza**

Michel **Delforge**

Julio **Delgado**

Matteo **Della Porta**

Rome

Jacksonville

Boston

Houston

Milan

Reggio Emilia

Palermo

Turin

Pisa

Madison

Seattle

Meldola (FC)

Jacksonville

Turin

Houston

Turin

Ferrara

Houston

Milan

Madrid

Campinas

Leuven

Barcelona

Milan



Enrico Derenzini	Milan
Daniele Derudas	Cagliari
Courtney DiNardo	Houston
Konstanze Doehner	Ulm
Massimo Dominici	Modena
Jean El Cheikh	Beirut
Brunangelo Falini	Perugia
Alessandra Ferrajoli	Houston
Felicetto Ferrara	Naples
Andres Ferreri	Milan
Robin Foà	Rome
Sara Fratcelli	Pavia
Gianluca Gaidano	Novara
Sara Galimberti	Pisa
Carlo Gambacorti-Passerini	Milan
Guillermo Garcia-Manero	Houston
Irene Ghobrial	Boston
Domenico Girelli	Verona
Shakira Jeanene Grant	Chapel Hill
Birol Guvenc	Adana
Hamed Hanan	Cairo
Ilaria Iacobucci	Memphis
Lorenzo Iovino	Seattle
Ahmad Ibrahim	Beirut
Elias Jabbour	Houston
Nitin Jain	Houston



FACULTY

Tapan **Kadia**

Hagop **Kantarijan**

Rami **Komrokji**

Marina **Konopleva**

Francesco **Lanza**

Hans **Lee**

Arcangelo **Liso**

Franco **Locatelli**

Alessandro **Lucchesi**

Stefano **Luminari**

Angelo **Maiolino**

Fabio **Malavasi**

Giovanni **Marconi**

Maria Paola **Martelli**

Giovanni **Martinelli**

Massimo **Massaia**

Maria Victoria **Mateos**

Massimiliano **Mazza**

Mauricette **Michallet**

Filippo **Milano**

Mohamad **Mohty**

Vittorio **Montefusco**

Philippe **Moreau**

Adrian **Mosquera**

Houston

Houston

Tampa

New York

Ravenna

Houston

Foggia

Rome

Meldola (FC)

Reggio Emilia

Rio de Janeiro

Turin

Meldola (FC)

Perugia

Meldola (FC)

Cuneo

Salamanca

Meldola

Lyon

Seattle

Paris

Milan

Nantes

Madrid



Tariq Mughal	Boston
Nikhil Munshi	Boston
Gerardo Musuraca	Meldola (FC)
Arnon Nagler	Tel Aviv
Ernesta Paola Neri	Calgary
Esther Oliva	Reggio Calabria
Attilio Olivieri	Ancona
Livio Pagano	Rome
Bruno Paiva	Salamanca
Aneel Paulus	Jacksonville
Naveen Pemmaraju	Houston
Antonello Pinto	Naples
Concetta Quintarelli	Rome
Farhad Ravandi	Houston
Karthik Ramasamy	Oxford
Roberto Ria	Bari
Jose Maria Ribera	Barcelona
Paul G. Richardson	Boston
Alessandra Romano	Catania
Marianna Rossi	Pavia
Gianantonio Rosti	Meldola (FC)
Giuseppe Saglio	Turin
Jesus San-Miguel	Navarra
Evangelos Terpos	Athens
Steve Treon	Boston
Calogero Vetro	Catania




Katja **Weisel**

Amer **Zeidan**

Hamburg

New Heaven

ORAL COMMUNICATIONS FACULTY





Key Information

VENUE

A. ROMA LIFESTYLE HOTEL

Via Giorgio Zoega, 59, 00164 Roma, Italy

MEETING

Tuesday, Oct. 03	12.00 - 19.30
Wednesday, Oct. 04	08.30 - 20.00
Thursday, Oct. 05	08.30 - 19.30
Friday, Oct. 06	08.30 - 19.00

SOCIAL MEDIA

Soho Italy is active on various social media platform. Follow us on the networks below and get real-time updates:

INTERNET

WiFi is available in all areas.





General Information

LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

CLIMATE

The average temperature is around 16–27 degrees.

BANKING SERVICE

The official currency in Rome is the Euro. Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 08:30 to 13:30.

HOTEL INFORMATION

For hotel information and reservations please visit the Hotels & Groups Desk.

TAXI

The single number to call a taxi is 060609

For other utilities on the taxi service, see www.060608.it

The journey to/ from Fiumicino Airport: 48€

The journey to/ from Ciampino Airport: 30€

The rates from Termini railway station to the city centre should cost between € 8 - € 15.



Public Transport



Termini railway station is 10 km from the hotel.

The hotel is connected to the center of Rome by tram line no. 8. The nearest tram stop can be reached on foot from the hotel and the tram will take you directly to Piazza Venezia in 15-20 minutes.

A.Roma Lifestyle Hotel also offers a shuttle service to and from the city center, available from 8.30 to 21.00. Reservation required.





Program Table

Tuesday, Oct. 03

08.00

09.00

10.00

11.00

12.00

ADAPTIVE Pre-Opening Lunch Symposium

13.00

Session 1: Opening Session

14.00

Session 2: Acute Lymphoblastic Leukemia - Clinical Session 1

15.00

16.00

Session 3: Acute Lymphoblastic Leukemia - Clinical Session 2

17.00

18.00

Session 4: Allogeneic stem cell transplantation in hematological malignancies: dead or alive and kicking?

19.00

**Session 5: CAR-T in Hematological malignancies:
from dream to reality**

20.00

21.00

**Sponsored Symposium by CURIS
IRAK4 in Hematologic malignancies**

22



Program Table

Wednesday, Oct. 04

07.00

08.00

Breakfast with the Professors

09.00

**Sponsored Symposium by MENARINI STEMLINE
Tagraxofusp: a new innovative target therapy for BPDCN patients**

10.00

Session 6: Acute Myeloid Leukemia – State of the art

11.00

12.00

Session 7: Acute Myeloid Leukemia – State of the art 2

13.00

14.00

Session 8: Acute Myeloid Leukemia – Clinical Session

15.00

16.00

Session 9: Acute Myeloid Leukemia – Clinical Session

17.00

Session 10: Myeloproliferative Neoplasms - State of the art

18.00

19.00

Session 11: Chronic Lymphocytic Leukemia

20.00



Program Table

Thursday, Oct. 05

07.00

08.00

09.00

Breakfast with the Professors

10.00

FLT3 Inhibitors in Acute Leukemias

11.00

Session 12: Chronic Myeloid Leukemia – State of the art

12.00

Session 13: Myelodysplastic Syndromes - State of the art

13.00

14.00

15.00

**Session 14: Non-Hodgkin and Hodgkin Lymphomas:
State of the art**

16.00

17.00

Session 14: Hodgkin Lymphomas: State of the art

18.00

Session 15: Spotlights on rare entities and non-malignant diseases

19.00

20.00

24



Program Table

Friday, Oct. 06

07.00

08.00

Breakfast with the Professors

09.00

Sponsored Symposium ONCOPEPTIDES

10.00

Session 16: Multiple Myeloma - Biology

11.00

SOHO Italy – EHOc Joint Lecture

12.00

Session 17: Multiple Myeloma – Clinical Session 1

13.00

14.00

Session 18: Multiple Myeloma – Clinical Session 2

15.00

Session 19: Smoldering Myeloma

16.00

**Session 20: Mayo Clinic - SOHO Italy Joint Symposium
Open questions in Multiple Myeloma**

17.00

18.00

Session 21: Multiple Myeloma – Clinical Session 3

19.00

20.00



03
10.23



12.00 - 13.00 ADAPTIVE PRE-OPENING LUNCH SYMPOSIUM

Is it now the time to move MRD into clinical trials and into routine testing?

Chairs: C. Cerchione, E. Jabbour

MRD preclinical data for ALL patients

G. Martinelli

MRD clinical data and cases for ALL patients

E. Jabbour, N. Daver

MRD preclinical data for MM patients

K. Ramasamy

MRD clinical data and cases for MM patients

C. Cerchione

SESSION 1 • OPENING SESSION

Chairs: C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian, G. Martinelli

13:00 - 13:10 WELCOME AND INTRODUCTION

What is SOHO Italy and next steps

C. Cerchione, H. Kantarjian, G. Martinelli

SESSION 2 • ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL SESSION 1

Chairs: C. Cerchione, E. Jabbour, H. Kantarjian, G. Martinelli

13.30 - 13.45 How I manage Acute Lymphoblastic Leukemia at MDACC

H. Kantarjian

13.45 - 14.00 How I manage Elderly Acute Lymphoblastic Leukemia at MDACC

E. Jabbour

14.00 - 14.15 How I manage Acute Lymphoblastic Leukemia in Europe

G. Martinelli

14.15 - 14.30 New insights in Acute Lymphoblastic Leukemia: Chemotherapy-free regimen in Ph-positive ALL

E. Jabbour



Tuesday, Oct. 03

14.30 - 14.45 GIMEMA in Acute Lymphoblastic Leukemia: past, present and future

R. Foà

14.45 - 14.55 Oral Communication 1 (ALL 1)

14.55 - 15.15 Discussion

SESSION 3 • ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL SESSION 2

Chairs: D. Cilloni, E. Jabbour, N. Jain, M. Konopleva

15.15 - 15.30 How to better integrate monoclonal antibodies in the current therapy of Acute Lymphoblastic Leukemia patients

D. Cilloni

15.30 - 15.45 New Cellular therapies in Adult Acute Lymphoblastic Leukemia: what's new?

N. Jain

15.45 - 16.00 Ph-like Acute Lymphoblastic Leukemia

M. Konopleva

16.00 - 16.15 CAR-T versus allogenic stem cell transplantation in relapsed/refractory Acute Lymphoblastic Leukemia

J. Ribera

16.15 - 16.30 The management of infectious complications during novel target therapies in Leukemia patients

L. Pagano

16.30 - 16.40 Oral Communication 2 (ALL 2)

16.40 - 16.55: Discussion

16.55 - 17.15: Coffee Break

17.15 - 17.30: Special Lecture from SOHO MENA:

How I manage Chronic Myeloid Leukemia at MDACC

E. Jabbour



SESSION 4 • ALLOGENIC STEM CELL TRANSPLANTATION IN HEMATOLOGICAL MALIGNANCIES: DEAD OR ALIVE AND KICKING?

Chairs: J. El Cheikh, M. Dominici, F. Milano, A. Nagler

17.30 - 17.45 New conditioning regimen pre-allogenic Stem cell transplantation

J. El Cheikh

17.45 - 18.00 Which is the role of Allogenic Stem cell transplantation in the era of CAR-T?

A. Nagler

18.00 - 18.15 How to develop a innovative cellular therapies center: from Clinical trials to real world data

F. Milano

18.15 - 18.30 Discussion

SESSION 5 • CAR-T IN HEMATOLOGICAL MALIGNANCIES: FROM DREAM TO REALITY

Chairs: G. Bolondi, J. Delgado, M. Dominici, F. Milano, A. Nagler

18.30 - 18.45 History of a success – First approved academic CAR-T in Europe

J. Delgado

18.45 - 19.00 The role of translational researcher in CAR-T: toward academic CAR-T

M. Mazza

19.00 - 19.15 How I overcome resistances in pediatric acute leukemias treated with new cellular therapies

C. Quintarelli



Tuesday, Oct. 03

19.15 - 19.30 How I manage complications after CAR-T and bispecific antibodies: the point of view from reanimation room

G. Bolondi

19.30 - 19.45 CAR-T in solid tumors – from research to clinical applications

M. Dominici

19.45 Conclusions and closing remarks Day 1

C. Cerchione, H. Kantarjian, G. Martinelli

20.30 - 21.30 SPONSORED SYMPOSIUM BY CURIS

IRAK4 in Hematologic malignancies

Chairs: C. Cerchione, N. Daver, G. Garcia-Manero, G. Martinelli

Spliceosome Mutations and the IRAK4 pathway

G. Martinelli (12 min)

FLT3 mutations and the IRAK4 pathway

G. Garcia-Manero (12 min)

Clinical experience with IRAK4 Inhibition in Myelodysplastic Syndromes and Acute Leukemias

G. Garcia-Manero (12 min)

IRAK4 Inhibition in Myeloma and Lymphoma

C. Cerchione (12 min)

Discussion and Conclusions

C. Cerchione, N. Daver, G. Garcia-Manero, G. Martinelli

A hand is shown reaching out from the left side of the frame towards a glowing, ethereal energy field on the right. The energy field consists of intricate, web-like patterns in shades of blue and purple, overlaid with bright red, glowing lines that form a complex, circular structure. The background is a dark blue-grey color with a subtle hexagonal grid pattern. The overall aesthetic is futuristic and high-tech.

04
10.23



Wednesday, Oct. 04

08.00 - 08.30 BREAKFAST WITH THE PROFESSORS

SPONSORED SYMPOSIUM BY MENARINI STEMLINE

Tagraxofusp: a new innovative target therapy for BPDCN patients

Chair: C. Cerchione

08.30 - 08.40 Introduction

G. Martinelli

08.40 - 09.00 Characterization and diagnosis of BPDCN

S. Fraticelli

09.00 - 09.20 Treatment and management of BPDCN: clinical data and long-term outcomes

G. Marconi, M. Rossi

09.20 - 09.30 Discussion

G. Martinelli

SESSION 6 • ACUTE MYELOID LEUKEMIA - STATE OF THE ART

Chairs: N. Daver, C. DiNardo, T. Kadia, H. Kantarjian, G. Martinelli

09.30 - 09.45 Overview of new and revised European LeukemiaNet Working Party guidelines: Importance of molecular testing in Acute Myeloid Leukemia and practical considerations for clinical practice

A. De La Fuente

09:45 - 10.00 How I manage Acute Myeloid Leukemia at MD Anderson Cancer Center

H. Kantarjian

10.00 - 10.15 Non-Intensive Treatment of Elderly/Unfit Patients with Acute Myeloid Leukemia at MDACC

T. Kadia

10.15 - 10.30 How I manage FLT3 mutated Acute Myeloid Leukemia: Moving Towards Cure

G. Martinelli



10.30 - 10.45 How I manage IDH-mutated Acute Myeloid Leukemia at MDACC

C. DiNardo

10.45 - 11.00 Immune and cellular approaches and role of Menin Inhibitors in Acute Myeloid Leukemia

N. Daver

11.00 - 11.10 Oral Communication 3 (AML 1)

11.10 - 11.20 Discussion

SESSION 7 • ACUTE MYELOID LEUKEMIA - STATE OF THE ART 2

Chairs: A. De La Fuente, K. Doehner, A. Olivieri, N. Pemmaraju

11.20 - 11.35 The role of molecular MRD monitoring in AML/NGS approaches

K. Doehner

11.35 - 11.50 Current role of allogenic stem cell transplantation and Maintenance in Acute Myeloid Leukemia

A. Olivieri

11.50 - 12.05 How I manage secondary Acute Myeloid Leukemia

F. Lanza

12.05 - 12.20 Special Lecture from SOHO France:

New insights in Acute Myeloid Leukemia

M. Michallet

12.20 - 12.30 Discussion

12.30 - 13.30 Lunch



Wednesday, Oct. 04

SESSION 8 • ACUTE MYELOID LEUKEMIA - CLINICAL SESSION

Chairs: M. Andreef, B. Falini, M.P. Martelli, F. Ravandi

13.30 - 13.45 Targeted therapy of NPM1-mutated Acute Myeloid Leukemia - State of the art

M.P. Martelli

13.45 - 14.00 Is All Oral Therapy of Acute Myeloid Leukemia a Reality for the Future?

F. Ravandi

14.00 - 14.15 New strategies in induction of transplant-eligible Acute Myeloid Leukemia

G. Marconi

14.15 - 14.30 TP53 in Myeloid Leukemias: Targeting the Guardian of the Genome

M. Andreeff

14.30 - 14.45 **Oral Communication 4 (AML 2)**

14.45 - 14.55 **Discussion**

SESSION 9 • ACUTE MYELOID LEUKEMIA - CLINICAL SESSION

Chairs: L. Brunetti, F. Ferrara, S. Galimberti, I. Iacobucci, A. Zeidan

14.55 - 15.05 Role of Immune Checkpoint Inhibitors in Acute Myeloid Leukemia

A. Zeidan

15.05 - 15.20 NPM1 mutated AML: from bench to bedside

L. Brunetti

15.20 - 15.35 The pathogenesis of acute leukemias: approaches and molecular insights

I. Iacobucci

15.35 - 15.50 Digital droplet PCR in Hematologic malignancies: a new useful molecular tool

S. Galimberti



15.50 - 16.00 Oral Communication 5 (AML 3)

16.00 - 16.10 Discussion

SESSION 10 • MYELOPROLIFERATIVE NEOPLASMS - STATE OF THE ART

Chairs: A. Liso, A. Lucchesi, T. Mughal

16.10 – 16.25 New insights in hemoglobinopathies and iron deficiency anemia

D. Girelli

16.25 - 16.55 Importance of correct diagnosis in Myeloproliferative Neoplasms

- Updates on WHO Classification of Myeloproliferative Neoplasms

H. Hamed

- From correct diagnosis to personalized medicine for Myeloproliferative Neoplasms

T. Mughal

16.55 - 17.10 A new pathogenetic paradigm for Myeloproliferative Neoplasms: the “circulating wound”

A. Lucchesi

17.10 - 17.25 Pregnancies in Myeloproliferative Neoplasms: how to manage these patients

E. Abruzzese

17.25 - 17.35 Oral Communication 6 (MPN 1)

17.35 - 17.45 Discussion



Wednesday, Oct. 04

SESSION 11 • CHRONIC LYMPHOCYTIC LEUKEMIA

Chairs: A. Cuneo, A. Ferrajoli, G. Gaidano, M. Massaia

17.45 - 18.00 How I manage Chronic Lymphocytic Leukemia at MDACC

A. Ferrajoli

18.00 - 18.15 How I manage Chronic Lymphocytic Leukemia in Italy

A. Cuneo

18.15 - 18.30 Role of monitoring and MRD in Chronic Lymphocytic Leukemia: when and why?

M. Massaia

18.30 - 18.45 Which current sequencing in chronic lymphocytic leukemia's real world? -

G. Gaidano

18.45 - 19.00 How to improve the use novel agents in elderly CLL

A. Ibrahim

19.00 - 19.15 CAR T-cell therapy for Chronic Lymphocytic Leukemia: a new addition to our treatment toolbox?

L. Iovino

19.15 - 19.25 Discussion

19.25 Conclusions and closing remarks Day 2

C. Cerchione, H. Kantarjian, G. Martinelli

Authorities' talks:

20.00 - 20.10 SOHO USA - Introduction of SOHO USA and its role

N. Daver, E. Jabbour, H. Kantarjian

20.10 - 20.20 IRST - Introduction of IRST and its role

R. Maffioli, F. Miserocchi, M.T. Montella

20.20 - 20.30 EHA Introduction of EHA and its role

K. Doehner



20.30 - 20.40 COSTEM - Introduction of COSTEM and its role

A. Nagler

20.40 - 20.50 AIOM -Introduction of AIOM and its role

S. Cinieri

20.50 - 21.00 SOHO France - Introduction of SOHO France and its role


M. Michallet

21.00 - 21.10 SOHO MENA - Introduction of SOHO USA and its role

A. Ibrahim, E. Jabbour

21.10 - 21.20 EHOQ/SOHO Turkey - Introduction of SOHO Turkey and its role

B. Güvenç, G. Saglio



05
10.23



08.30 - 09.00 BREAKFAST WITH THE PROFESSORS

09.00 - 10.00 FLT3 INHIBITORS IN ACUTE LEUKEMIAS

Chair: G. Martinelli

09.00 - 09.15 The diagnostic of FLT3: present and future

G. Marconi

09.15 - 09.30 How I treat FLT3 positive leukemias

G. Martinelli

09.30 - 09.45 Efficacy and new insight in hematological malignancies FLT3 positive with FLT3 inhibitors

G. Martinelli

09.45 - 09.55 Discussion

09.55 - 10.15 Coffee Break

SESSION 12 • CHRONIC MYELOID LEUKEMIA – STATE OF THE ART

Chairs: C. Gambacorti-Passerini, G. Martinelli

10.15 - 10.40 The transition from interferon to TKI therapy

C. Gambacorti-Passerini

10.40 - 10.55 Treatment-free remission - State of the art

G. Rosti

10.55 - 11.05 Oral Communication 8 (CML 1)

11.05 - 11.20 Discussion



Thursday, Oct. 05

SESSION 13 • MYELODYSPLASTIC SYNDROMES - STATE OF THE ART
Chairs: S. Colla, M. Dalla Porta, G. Garcia Manero, R. Komrokji, E. Oliva

11.20 - 11.35 Updates and new insights in the biology of Myelodysplastic Syndromes

S. Colla

11.35 - 11.50 Updates on classification and risk stratification for MDS

R. Komrokji

11.50 - 12.05 A Practical Approach to Molecular Pathology of Myelodysplastic Syndromes

M. Della Porta

12.05 - 12.20 Treatment of Lower Risk Myelodysplastic Syndromes

E. Oliva

12.20 - 12.35 Management of High-Risk Myelodysplastic Syndromes in MDACC: a total approach

G. Garcia-Manero

12.35 - 12.50 Target-therapies in Myelodysplastic syndromes: where are we going

E. Crisà

12.50 - 13.00 Oral Communication 8 (MDS 1)

13.00 - 13.10 Discussion

13.10 - 14.20 Lunch



SESSION 14 • NON-HODGKIN AND HODGKIN LYMPHOMAS: STATE OF THE ART

Chairs: E. Derenzini, A. Ferreri, A. Mosquera, S. Luminari, G. Musuraca

14.20 - 14.35 How I manage Diffuse Large B-Cell Lymphoma in Europe
G. Musuraca

14.35 - 14.50 How I manage Follicular, marginal zone and mantle cell Lymphoma
S. Luminari

14.50 - 15.05 How to integrate the new diagnostic tools in the current daily management of Non Hodgkin Lymphomas
E. Derenzini

15.05 - 15.20 How I manage CNS lymphomas
A. Ferreri

15.20 - 15.35 New scores in NHL using genomics and machine learning: from prognostication to optimal treatment selection
A. Mosquera

15.35 - 15.45 Oral

15.45 - 15.55 Discussion

15.55 - 16.10 Coffee Break



Thursday, Oct. 05

SESSION 14 • HODGKIN LYMPHOMAS: STATE OF THE ART

Chairs: A. Cashen, E. Derenzini, C. De Souza, A. Ferreri, G. Musuraca

16.10 - 16.25 How I manage Hodgkin in Disease in USA

A. Cashen

16.25 - 16.40 How I manage high stage newly diagnosed Hodgkin Lymphoma: toward a new standard of care?

C. De Souza

16.40 - 16.50 Oral Communication 9 (NHL 1)

16.50 - 17.00 Discussion

SESSION 15 • SPOTLIGHTS ON RARE ENTITIES AND NON-MALIGNANT DISEASES

Chairs: H.C. Lee, A. Romano, S. Treon, C. Vetro

17.00 - 17.15 How I manage Waldenstrom's Macroglobulinemia in the era of novel agents

S. Treon

17.15 - 17.30 How I manage AL Amyloidosis at MDACC

H.C. Lee

17.30 - 17.45 How I manage advanced systemic mastocytosis

A. Romano

17.45 - 17.55 Oral Communication 10 (HL 1)

17.55 - 18.00 Discussion

18.00 Conclusions and closing remarks Day 3

C. Cerchione, H. Kantarjian, G. Martinelli



06
10.23



Friday, Oct. 06

08.00 - 08.30 BREAKFAST WITH THE PROFESSORS

08.30 - 09.15 SPONSORED SYMPOSIUM ONCOPEPTIDES

The role of melphalan flufenamide in the Triple Class Refractory (TcR) MM patients

Chair: C. Cerchione

Melphalan flufenamide mechanism of action in TcR: present and future synergisms

E. Terpos

Current Clinical Positioning of melphalan flufenamide

C. Cerchione

How to treat elderly patients: the role of melphalan flufenamide

V. Montefusco

How to treat difficult patients and/or heavily pre-treated Patients (EMD, renal failure..)

K. Weisel

Discussion and closing remarks

C. Cerchione

SESSION 16 • MULTIPLE MYELOMA - BIOLOGY

Chairs: N. Bolli, E.P. Neri, B. Paiva, A. Vacca

09.15 - 09.30 How and when to integrate flow cytometry in daily practice of Multiple Myeloma

B. Paiva

09.30 - 09.45 Genomics of Smoldering Multiple Myeloma: from basic science to clinical applications

M.C. Da Via

09.45 - 10.00 Determinants of Resistance to CAR-T and T-cell Engagers in Multiple Myeloma

E.P. Neri



10.00 - 10.15 Targeting the bone marrow microenvironment in Multiple Myeloma

C. Botta

10.15 - 10.30 New insights in anti-angiogenesis in Multiple Myeloma

R. Ria and G. A. Solimando

10.30 - 10.40 Oral Communication 12 (MM 1)

10.40 - 10.50 Discussion

10.50 - 11.15 Coffee Break

SOHO ITALY – SOHO TURKEY/EHOG JOINT LECTURE

Chairs: C. Cerchione, D. Cilloni, B. Güvenç, G. Martinelli, G. Saglio

11.15 – 11.30 What is EHOG/SOHO Turkey and New insights from EHOG-SOHO Turkey

B. Güvenç, G. Saglio

SESSION 17 • MULTIPLE MYELOMA – CLINICAL SESSION 1

Chairs: K.C. Anderson, C. Cerchione, H.C. Lee, M.V. Mateos, P. Moreau

11.30 - 11.45 Multiple Myeloma: State of the art in Europe

C. Cerchione

11.45 - 12.00 Multiple Myeloma: State of the art in USA

H.C. Lee

12.00 - 12.15 Multiple myeloma cured in 2030: what are the next steps?

K.C. Anderson

12.15 - 12.30 Special Lecture - EHA-ESMO

Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up in Multiple Myeloma: what is changing?

P. Moreau



Friday, Oct. 06

12.30 - 12.45 Discussion

12.45 - 13.30 Lunch

SESSION 18 • MULTIPLE MYELOMA – CLINICAL SESSION 2

Chairs: C. Cerchione, A. Maiolino, V. Montefusco, P. Richardson, J. San-Miguel

13.30 - 13.45 How I manage Transplant Multiple Myeloma in frontline setting
V. Montefusco

13.45 - 14.00 Is anti-CD38-based induction therapy for every patient?
P. Richardson

14.00 - 14.30 New insights and opportunities for Lenalidomide - refractory patients

CAR-T
J. San-Miguel versus **STANDARD OF CARE**
A. Maiolino

14.30 – 14.40 Discussion

SESSION 19 • SMOLDERING MYELOMA

Chairs: N. Callander, C. Cerchione, I. Ghobrial, M.V. Mateos, P. Richardson

14.40 - 14.55 Is it time for biomarkers-driven approach in Smoldering Myeloma and Multiple Myeloma?
I. Ghobrial

14.55 - 15.10 How I manage Smoldering Multiple Myeloma In Europe
M.V. Mateos

15.10 - 15.25 How I manage Smoldering Multiple Myeloma in USA
N. Callander

15.25 - 15.35 Oral Communication 12 (MM 2)

15.35 - 15.45 Discussion



SESSION 20 • MAYO CLINIC - SOHO ITALY JOINT SYMPOSIUM - OPEN QUESTIONS IN MULTIPLE MYELOMA

Chairs: S. Ailawadhi, B. Bruno, C. Cerchione, A.A. Chanan-Khan, F. Malavasi, A. Paulus, M. Mohty

15.45 - 16.00 CD38: reflecting on the past to move to the future
F. Malavasi

16.00 - 16.15 Time for new targets: Bench-to-Bedside Development of Bcl-2 inhibitors for Treatment of Multiple Myeloma and lymphoproliferative disorders
A. Paulus

16.15 - 16.30 How to integrate bispecific antibodies in current therapeutic scenario of Multiple Myeloma
S. Ailawadhi

16.30 - 17.00 CAR-T in 2023 in Multiple Myeloma: Have We the promised land?
In Europe - B. Bruno
In USA - A.A. Chanan-Khan

17.00 -17.15 Will autologous Stem cell transplantation be replaced by CAR-T in Multiple Myeloma?
M. Mohty

17.15 - 17.25 Discussion

SESSION 21 • MULTIPLE MYELOMA – CLINICAL SESSION 3

Chairs: G. Buda, S.J. Grant, NC Munshi, A. Romano, E. Terpos

17.25 - 17.40 How I manage elderly and unfit patients
G. Buda

17.40 - 17.55 How I manage bone disease and its complications in Multiple Myeloma
E. Terpos

17.55 - 18.05 Which is the correct sequencing of novel agents and combinations in relapsed/refractory Multiple Myeloma
A. Romano



Friday, Oct. 06

18.05 - 18.20 How I manage extramedullary disease and plasma cell leukemia

D. Derudas

18.20 - 18.35 Health-related quality of life in relapsed and refractory multiple myeloma

M. Delforge

18.35 - 18.55 Merging Molecular and Aging Assessments to Guide Therapy in Older Patients With Myeloma

S. J. Grant

18.55 - 19.05 Life after CAR-T and bispecific: from trials to real world

N.C. Munshi

19.05 - 19.15 Discussion

19.15 Prizes and Conclusions. See you next year

C. Cerchione, H. Kantarjian, G. Martinelli

A photograph of the St. Peter's Basilica dome in Rome, Italy, taken during sunset. The dome is the central focus, with its intricate architectural details and the bronze statue of St. Peter on a horse visible. The sky is a mix of orange and purple, and the overall scene is bathed in the warm light of the setting sun. The text "SEE YOU NEXT YEAR!" is overlaid in large, white, bold, sans-serif font in the upper right quadrant.

SEE YOU
NEXT
YEAR!



**SUPPORTED BY
AN UNRESTRICTED
EDUCATIONAL
GRANT
FROM**



DIAMOND

Stemline[®]

A Menarini Group Company

PLATINUM

abbvie

GOLD

Adaptive
biotechnologies™

CURIS[®]

SILVER

 **astellas**
for virtual platform

 **BeiGene**


Daiichi-Sankyo

 **oncopeptides**

BRONZE

 **ARROW**
DIAGNOSTICS

 **AstraZeneca**

 **blueprint**
MEDICINES

immun•gen

 **janssen Oncology**
PHARMACEUTICAL COMPANY OF Johnson & Johnson

 **MASSIVEBIO**

 **Pfizer**

 **Protagonist**
Therapeutics

 **prothena**

sanofi

werfen



Follow Us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is #SOHOItaly

You can use it on Facebook, Twitter, Instagram, Youtube and LinkedIn.

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly

@SocietyofHemOnc

@IRSTufficiale

@MDAndersonNews

@pro_eventi

@GMartinelli2

@DottorClaudio

@DrHKantarjian

Enjoy & Share your experience!

Follow us






Media Partners

PHARMASTAR[★]
il Giornale online sui Farmaci

VJHEMONC
The Video Journal of Hematological Oncology

 **VuMedi**



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUT
ROMAGN
PER LO
DEI TUM
DINO AMADORI